Impact of Concomitant Thiopurine on the Efficacy and Safety of Filgotinib in Patients with Ulcerative Colitis: Post Hoc Analysis of the Phase 2b/3 SELECTION Study
Open Access
- 29 November 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 18 (6) , 801-811
Abstract
SELECTION is the first study to assess the impact of concomitant thiopurine and other immunomodulator [IM] use on the efficacy and safety of a Janus kinase inhibitor, filgotinib, in patients with ulcerative colitis. Data from the phase 2b/3 SELECTION study were used for this post hoc analysis. Patients were randomized [2:2:1] to two induction studies [biologic-naive, biologic-experienced] to filgotinib 200 mg, 100 mg, or placebo. At week 10, patients receiving filgotinib were re-randomized [2:1] to continue filgotinib or switch to placebo until week 58 [maintenance]. Outcomes were compared between subgroups with and without concomitant IM use. At week 10, a similar proportion of patients in +IM and −IM groups treated with filgotinib 200 mg achieved Mayo Clinic Score [MCS] response [biologic-naive: 65.8% vs 66.9%; biologic-experienced: 61.3% vs 50.5%] and clinical remission [biologic-naive: 26.0% vs 26.2%; biologic-experienced: 11.3% vs 11.5%]. At week 58, a similar proportion of patients in +IM and −IM groups treated with filgotinib 200 mg achieved MCS response [biologic-naive: 74.2% vs 75.0%; biologic-experienced: 45.5% vs 61.4%] and clinical remission [biologic-naive: 51.6% vs 47.4%; biologic-experienced: 22.7% vs 24.3%]. The probability of protocol-specified disease worsening during the maintenance study in patients treated with filgotinib 200 mg did not differ between +IM and −IM groups [p = 0.6700]. No differences were observed in the incidences of adverse events between +IM and −IM groups in induction/maintenance studies. The efficacy and safety profiles of filgotinib treatment in SELECTION did not differ with or without concomitant IM use.Keywords
Funding Information
- Gilead Sciences, Inc
This publication has 22 references indexed in Scilit:
- Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trialThe Lancet, 2017
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2017
- Ulcerative colitisThe Lancet, 2017
- Adalimumab Monotherapy and a Combination with Azathioprine for Crohn’s Disease: A Prospective, Randomized TrialJournal of Crohn's and Colitis, 2016
- Optimal management of steroid-dependent ulcerative colitisClinical and Experimental Gastroenterology, 2015
- Systematic review with meta‐analysis: infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitisAlimentary Pharmacology & Therapeutics, 2015
- Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative ColitisGastroenterology, 2014
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseNew England Journal of Medicine, 2010
- Clinical pharmacology and pharmacogenetics of thiopurinesEuropean Journal of Clinical Pharmacology, 2008
- A reproducible grading scale for histological assessment of inflammation in ulcerative colitisGut, 2000